New styrene-b-isobutylene-b-styrene (SIBS) glaucoma drainage implant

Marcia Orozco; Ana C. Acosta; Edgar M. Espana; Leonard Pinchuk; Bruce A. Weber; Stewart Davis; Esdras Arrieta; Sander Dubovy; Francisco Fantes; Mohamed Aly; Yonghua Zhou; Jean-Marie Parel

doi:10.1117/12.652297

7 March 2006 New styrene-b-isobutylene-b-styrene (SIBS) glaucoma drainage implant

Marcia Orozco, Ana C. Acosta, Edgar M. Espana, Leonard Pinchuk, Bruce A. Weber, Stewart Davis, Esdras Arrieta, Sander Dubovy, Francisco Fantes, Mohamed Aly, Yonghua Zhou, Jean-Marie Parel

Author Affiliations +

Proceedings Volume 6138, Ophthalmic Technologies XVI; 61380U (2006) https://doi.org/10.1117/12.652297
Event: SPIE BiOS, 2006, San Jose, California, United States

Abstract

Purpose: To design and test the Miami-InnFocus Drainage Implant (MiDi) as a glaucoma shunt that is biocompatible, flexible, and significantly smaller than existing commercial implants in order to prevent postoperative hypotony, inflammation, scarring, erosion, and extrusion. Methods: A new biomaterial composed of styrene-b-isobutylene-b-styrene (SIBS) was used in a novel design for a glaucoma drainage implant. The implant consists of a tube 11mm long with an inner diameter of 70, 100, and 150 μm and outer diameter of 250 μm with a 1mm² tab located 4.5mm from the proximal tip to prevent migration. The device was implanted in 15 New Zealand White rabbits for biocompatibility and efficacy testing. A similarly designed implant made of polydimethylsiloxane was implanted in 6 other animals as a pseudo-control. Typical GDI implantation technique was modified for this device. The proximal end of the new SIBS implant was inserted 2mm into the anterior chamber and the distal end placed in a subconjunctival space created by the surgeon. Biocompatibility of the device was studied by slit-lamp follow-up and intraocular pressure (IOP) measurements recorded periodically. Results: Biocompatibility of the MiDi was excellent. A low and diffuse bleb was observed with these devices. All SIBS tubes were patent 9 months after insertion. Immunostaining demonstrated non-continuous deposition of collagen with virtually no encapsulation. No macrophages or myofibroblast were visible around the SIBS polymer which was found more bioinert than the control PDMS. Conclusion: This newly designed glaucoma implant is clinically biocompatible in the rabbit model and maintained 100% patency at 9 months.

Citation Download Citation

Marcia Orozco, Ana C. Acosta, Edgar M. Espana, Leonard Pinchuk, Bruce A. Weber, Stewart Davis, Esdras Arrieta, Sander Dubovy, Francisco Fantes, Mohamed Aly, Yonghua Zhou, and Jean-Marie Parel "New styrene-b-isobutylene-b-styrene (SIBS) glaucoma drainage implant", Proc. SPIE 6138, Ophthalmic Technologies XVI, 61380U (7 March 2006); https://doi.org/10.1117/12.652297

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available